Loading…
Immuneering Corporation is projected to rise to $6.93 by 2027, a +30% move from its current price of $5.34. IMRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.20 | $5.34 | $5.48 | +0.03% |
| May 30 | $5.14 | $5.34 | $5.54 | +0.06% |
| May 31 | $5.10 | $5.34 | $5.59 | +0.09% |
| Jun 1 | $5.06 | $5.34 | $5.64 | +0.11% |
| Jun 2 | $5.03 | $5.34 | $5.67 | +0.14% |
| Jun 3 | $5.00 | $5.34 | $5.71 | +0.17% |
| Jun 4 | $4.98 | $5.35 | $5.74 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.98 | $5.35 | $5.74 | +0.20% |
| Week 2 | $4.84 | $5.36 | $5.92 | +0.40% |
| Week 3 | $4.75 | $5.37 | $6.07 | +0.60% |
| Week 4 | $4.67 | $5.38 | $6.20 | +0.80% |
| Week 5 | $4.60 | $5.39 | $6.32 | +1.00% |
| Week 6 | $4.54 | $5.40 | $6.43 | +1.21% |
| Week 7 | $4.48 | $5.41 | $6.53 | +1.41% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immuneering Corporation is a healthcare company focused on oncology in the United States. It develops medicines for broad populations of cancer patients, including IMM-1-104 (atebimetinib), a dual-MEK inhibitor in a Phase 3 clinical trial for pancreatic cancer and non-small cell lung cancer caused by mutations in RAS or RAF, and IMM-6-415 (envometinib), in Phase 1/2a for solid tumors. The company was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Immuneering Corporation trades under the IMRX symbol. It has a current price of $5.39 and a market cap of $348.72M, with rank 3367. The stock sits in a defined price channel with a 30-day range from $4.48 to $6.48, and a nearby resistance noted at $6.13 and support at $4.87.
Forecasts show a path of valuation that begins with a 2026 average price of $5.39 and rises in subsequent years to $7.32 (2027), $8.58 (2028), $10.62 (2029), and $14.39 (2030). The sentiment shifts to BULLISH from 2027 onward, aligning with rising price expectations and progressively higher ROI figures, reaching 166.9% by 2030 and higher thereafter.
A major floor 21.6% below — a decisive break under it would weaken the trend.
The nearest floor, 8.7% below — buyers have tended to step in here.
The nearest ceiling, 14.9% above — a clean break opens room to run.
A major ceiling 25.7% above — clearing it would confirm fresh momentum.
Key IMRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.25 | Buy | $5.26 | Buy |
| MA 10 | $5.17 | Buy | $5.22 | Buy |
| MA 20 | $5.21 | Buy | $5.25 | Buy |
| MA 50 | $5.32 | Buy | $5.31 | Buy |
| MA 100 | $5.23 | Buy | $5.36 | Sell |
| MA 200 | $5.79 | Sell | $5.15 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.87 | Neutral |
| Stoch RSI (14) | 89.85 | Sell |
| CCI (20) | 76.56 | Neutral |
| Williams %R (14) | -10.58 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 2.20 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 89.42 | Sell |
| TRIX (15) | -0.20 | Sell |
| Awesome (5,34) | -0.15 | Sell |
| Ultimate (7,14,28) | 55.89 | Neutral |
| Momentum (10) | 0.16 | Buy |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 5.39 | Sell |
| ADX (14) | 10.44 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is bullish, with RSI(14) at 50 and moving averages suggesting upward drift. The SMA50 is $5.31 and the SMA200 is $5.77, placing near-term momentum near the current price.
Support sits at $4.87 and resistance at $6.13, framing a near-term trading range around the $5 area. The 30-day range spans from $4.48 to $6.48, indicating a defined tightening range as buyers and sellers converge in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.14 | $5.34 | $7.59 | 0% | Neutral | |
| $5.50 | $6.93 | $9.23 | +30% | Bullish | |
| $6.15 | $7.94 | $10.97 | +49% | Bullish | |
| $7.07 | $9.35 | $13.27 | +75% | Bullish | |
| $9.22 | $12.43 | $18.07 | +133% | Bullish | |
| $11.18 | $15.35 | $22.77 | +188% | Bullish | |
| $11.67 | $16.29 | $24.63 | +205% | Bullish | |
| $12.66 | $17.96 | $27.62 | +237% | Bullish | |
| $13.48 | $19.41 | $30.31 | +264% | Bullish | |
| $14.49 | $21.18 | $33.55 | +297% | Bullish | |
| $23.00 | $35.87 | $60.37 | +572% | Bullish | |
| $53.69 | $93.71 | $172.34 | +16.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.14 | $5.34 | $6.30 | +0.00% |
| June 2026 | $4.72 | $5.54 | $6.65 | +3.80% |
| July 2026 | $4.63 | $5.48 | $6.67 | -1.12% |
| August 2026 | $4.59 | $5.46 | $6.72 | -0.21% |
| September 2026 | $4.74 | $5.68 | $7.04 | +3.90% |
| October 2026 | $4.82 | $5.80 | $7.25 | +2.12% |
| November 2026 | $4.78 | $5.78 | $7.28 | -0.22% |
| December 2026 | $4.94 | $6.00 | $7.59 | +3.67% |
Click any year to see its month-by-month IMRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, IMRX is projected to trade between $4.14 and $7.59, averaging $5.34 — a potential gain of 0% from today's $5.34. A consolidation phase looks the most probable path here.
Immuneering Corporation's 2027 outlook centres on $6.93, within a $5.50 to $9.23 range. That is up +30% on the projected 2026 average. That marks a +30% change versus current levels. Momentum favours further upside here.
By 2028, IMRX could reach as high as $10.97, with a base case around $7.94 and support toward $6.15 — roughly +49% from $5.34. Buyers look set to stay in control over this stretch.
Expect IMRX to range from $7.07 to $13.27 through 2029. The $9.35 average target implies a +75% move from current prices. That is up +18% on the projected 2028 average. Momentum favours further upside here.
The IMRX price prediction for 2030 points to an average of $12.43 (low $9.22, high $18.07) — a potential gain of +133% on today's $5.34. Buyers look set to stay in control over this stretch.
In 2031, IMRX is projected to trade between $11.18 and $22.77, averaging $15.35 — a potential gain of +188% from today's $5.34. That is up +23% on the projected 2030 average. Momentum favours further upside here.
Immuneering Corporation's 2032 outlook centres on $16.29, within a $11.67 to $24.63 range. That is up +6% on the projected 2031 average. That marks a +205% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, IMRX could reach as high as $27.62, with a base case around $17.96 and support toward $12.66 — roughly +237% from $5.34. Momentum favours further upside here.
Expect IMRX to range from $13.48 to $30.31 through 2034. The $19.41 average target implies a +264% move from current prices. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The IMRX price prediction for 2035 points to an average of $21.18 (low $14.49, high $33.55) — a potential gain of +297% on today's $5.34. Momentum favours further upside here.
In 2040, IMRX is projected to trade between $23.00 and $60.37, averaging $35.87 — a potential gain of +572% from today's $5.34. That is up +69% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Immuneering Corporation's 2050 outlook centres on $93.71, within a $53.69 to $172.34 range. That is up +161% on the projected 2040 average. That marks a +16.6x change versus current levels. Momentum favours further upside here.
Investing $1,000 in IMRX today (≈ 187.441425 IMRX) could be worth
$17,566.03
+$16,566.03 (+1657%) by 2050 · US Dollar
Based on the average projected IMRX price of $93.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMRXwould be worth at today's price.
$1,000 invested in IMRX on May 27, 2025 (≈ 609.756103 IMRX) would be worth
$3,253.05
+$2,253.05 (+225.3%) today · 3.25× · US Dollar
Based on a IMRX entry price of $1.64 vs. today's $5.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.02 | $1,062.75 | +6.3% |
| 1 month ago | $5.76 | $926.22 | -7.4% |
| 3 months ago | $4.99 | $1,069.14 | +6.9% |
| 6 months ago | $7.66 | $696.48 | -30.4% |
| 1 year ago | $1.64 | $3,253.05 | +225.3% |
| All time (4.8y) ago | $17.59 | $303.3 | -69.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMRX forecast.
Our base-case forecast reaches $11.00 around 2030.
Implied market cap at $11.00: $711.67M
The multi-year forecast shows a progressive rise in the average price from 2026 through 2050. The 2026 average is $5.39, followed by 2027 at $7.32, 2028 at $8.58, 2029 at $10.62, and 2030 at $14.39, with a 2030 ROI of 166.9% and a bullish outlook. Beyond 2030, 2040 is projected at an average of $46.10 and 2050 at $128.90, with ROIs of 755.3% and 2,291.4% respectively, both carrying bullish sentiment.
Other mid-to-late forecast years trend higher (2031 to 2035 show averages from $17.91 to $26.47, 2036+ not shown), while the overall trajectory remains bullish. These figures are estimates, not guarantees, and depend on future market dynamics and company progress. The forecast also reflects a substantial implied volatility, as evidenced by the listed ROIs, and should be considered in the context of risk and timing.
Tap a question to reveal the answer.
2030 avg $14.39; min $10.59; max $21.10; ROI 166.9%; sentiment BULLISH.
The forecast turns from Neutral in 2026 to Bullish from 2027 onward, with rising averages and ROIs: 2027 avg $7.32, 2028 avg $8.58, 2029 avg $10.62, 2030 avg $14.39 and 2050 avg $128.90, with ROI reaching 2291.4% by 2050.
Yes. The 2050 maximum forecast is $240.85, with a 2040 maximum of $78.64 and a 2030 maximum of $21.10.
Current price is $5.39; market cap is $348.72M; the 30-day range is $4.48 to $6.48.
IMM-1-104 (atebimetinib) is in Phase 3; IMM-6-415 (envometinib) is in Phase 1/2a. There are clinical supply agreements with Regeneron to evaluate atebimetinib with Libtayo in RAS-mutant NSCLC and with Eli Lilly to evaluate atebimetinib with olomorasib in KRAS G12C-mutant NSCLC.
Immuneering Corporation Community Discussion
0Share your Immuneering Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.